metadata toggle
For the treatment of dogs with, or at risk from, mixed external and internal parasitic infestations. The veterinary medicinal product is exclusively indicated when use against ticks, fleas or mites and gastrointestinal nematodes is indicated at the same time. The veterinary medicinal product also provides concurrent efficacy for the prevention of heartworm disease, angiostrongylosis and thelaziosis
For the treatment of tick infestations. The veterinary medicinal product has immediate and persistent tick killing activity for 5 weeks against Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus and for 4 weeks against Dermacentor reticulatus;
For the treatment of flea infestations (Ctenocephalides felis and Ctenocephalides canis). The veterinary medicinal product has immediate and persistent flea killing activity against new infestations for 5 weeks;
The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
For the treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis).
For the treatment of demodicosis (caused by Demodex canis).
Gastrointestinal nematodes
For the treatment of gastrointestinal roundworm and hookworm infections:
Toxocara canis immature adults (L5) and adults;
Ancylostoma caninum L4 larvae, immature adults (L5) and adults;
Toxascaris leonina adults;
Uncinaria stenocephala adults.
Other nematodes
For the prevention of heartworm disease (Dirofilaria immitis);
For the prevention of angiostrongylosis by reducing the level of infection with immature adult (L5) stages of Angiostrongylus vasorum.
For the prevention of establishment of thelaziosis (adult Thelazia callipaeda eyeworm infection).